{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T18:26:14Z","timestamp":1781893574904,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ftirma Kurumu","doi-asserted-by":"publisher","award":["216S304"],"award-info":[{"award-number":["216S304"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008222","name":"Universit\u00e9 de Montpellier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008222","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013811","name":"Medizinische Fakult\u00e4t, Universit\u00e4t Leipzig","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013811","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ejphar.2019.172803","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T11:17:42Z","timestamp":1573816662000},"page":"172803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Evaluation of pharmacochaperone-mediated rescue of mutant V2 receptor proteins"],"prefix":"10.1016","volume":"865","author":[{"given":"Beril","family":"Erdem Tuncdemir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice","family":"Mergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel","family":"Saglar Ozer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2019.172803_bib1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.phrs.2016.12.036","article-title":"Pharmacological chaperone approaches for rescuing GPCR mutants: current state, challenges, and screening strategies","volume":"117","author":"Beerepoot","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2019.172803_bib2","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.coph.2004.08.001","article-title":"Pharmacological chaperone action on G-protein-coupled receptors","volume":"4","author":"Bernier","year":"2004","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172803_bib3","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1681\/ASN.2005080854","article-title":"Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus","volume":"17","author":"Bernier","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2019.172803_bib4","doi-asserted-by":"crossref","first-page":"p1","DOI":"10.1159\/000245059","article-title":"Vasopressin type 2 receptor V88M mutation: molecular basis of partial and complete nephrogenic diabetes insipidus","volume":"114","author":"Bockenhauer","year":"2010","journal-title":"Nephron. Physiol."},{"key":"10.1016\/j.ejphar.2019.172803_bib5","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nature02265","article-title":"Therapeutic approaches to protein-misfolding diseases","volume":"426","author":"Cohen","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2019.172803_bib6","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12020-012-9704-1","article-title":"Mutations in the AVPR2, AVP-NPII, and AQP2 genes in Turkish patients with diabetes insipidus","volume":"42","author":"Duzenli","year":"2012","journal-title":"Endocrine"},{"key":"10.1016\/j.ejphar.2019.172803_bib7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1530\/EC-17-0236","article-title":"Functional characterization of AVPR2 mutants found in Turkish patients with nephrogenic diabetes insipidus","volume":"7","author":"Erdem","year":"2018","journal-title":"Endocr Connect"},{"key":"10.1016\/j.ejphar.2019.172803_bib8","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1681\/ASN.2005040371","article-title":"Molecular biology of hereditary diabetes insipidus","volume":"16","author":"Fujiwara","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2019.172803_bib9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev.med.46.1.331","article-title":"Molecular biology of diabetes insipidus","volume":"46","author":"Fujiwara","year":"1995","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejphar.2019.172803_bib10","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1600-0854.2004.00239.x","article-title":"Disease-causing V(2) vasopressin receptors are retained in different compartments of the early secretory pathway","volume":"5","author":"Hermosilla","year":"2004","journal-title":"Traffic"},{"key":"10.1016\/j.ejphar.2019.172803_bib11","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1007\/s004670100051","article-title":"Molecular and cellular defects in nephrogenic diabetes insipidus","volume":"16","author":"Knoers","year":"2001","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ejphar.2019.172803_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.phrs.2014.01.005","article-title":"Pharmacological chaperoning: a primer on mechanism and pharmacology","volume":"83","author":"Leidenheimer","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2019.172803_bib13","doi-asserted-by":"crossref","first-page":"22460","DOI":"10.1074\/jbc.M116.733220","article-title":"Analysis of the V2 vasopressin receptor (V2R) mutations causing partial nephrogenic diabetes insipidus highlights a sustainable signaling by a non-peptide V2R agonist","volume":"291","author":"Makita","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2019.172803_bib14","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0165-6147(00)01575-3","article-title":"Pharmacological chaperones: a new twist on receptor folding","volume":"21","author":"Morello","year":"2000","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2019.172803_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/164_2017_50","article-title":"Pharmacological chaperones as potential therapeutic strategies for misfolded mutant vasopressin receptors","volume":"245","author":"Mouillac","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172803_bib16","series-title":"Chemical Chaperones: Mechanisms of Action and Potential Use, Molecular Chaperones in Health and Disease","first-page":"405","author":"Papp","year":"2006"},{"key":"10.1016\/j.ejphar.2019.172803_bib17","first-page":"1703","article-title":"Functional characterization of the molecular defects causing nephrogenic diabetes insipidus in eight families","volume":"85","author":"Pasel","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2019.172803_bib18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12020-013-0043-7","article-title":"A large deletion of the AVPR2 gene causing severe nephrogenic diabetes insipidus in a Turkish family","volume":"46","author":"Saglar","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.ejphar.2019.172803_bib19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1527-3466.2001.tb00065.x","article-title":"An overview of SR121463, a selective non-peptide vasopressin V2 receptor antagonist","volume":"19","author":"Serradeil-Le Gal","year":"2001","journal-title":"Cardiovasc. Drug Rev."},{"key":"10.1016\/j.ejphar.2019.172803_bib20","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ckj\/sfy027","article-title":"Long-term outcome in inherited nephrogenic diabetes insipidus","volume":"12","author":"Sharma","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ejphar.2019.172803_bib21","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/nature02262","article-title":"Quality control in the endoplasmic reticulum protein factory","volume":"426","author":"Sitia","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2019.172803_bib22","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1152\/physrev.00029.2016","article-title":"Pharmacoperones as novel therapeutics for diverse protein conformational diseases","volume":"98","author":"Tao","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejphar.2019.172803_bib23","doi-asserted-by":"crossref","first-page":"47254","DOI":"10.1074\/jbc.M408154200","article-title":"Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors","volume":"279","author":"Wuller","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2019.172803_bib24","article-title":"A novel AVPR2 missense mutation in an Asian family with inherited nephrogenic diabetes insipidus: a case report","volume":"98","author":"Zhang","year":"2019","journal-title":"Medicine (Baltim.)"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919307551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919307551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:07:25Z","timestamp":1762142845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299919307551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":24,"alternative-id":["S0014299919307551"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.172803","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of pharmacochaperone-mediated rescue of mutant V2 receptor proteins","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.172803","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"172803"}}